Press Releases

Date Title and Summary
Toggle Summary Biogen and Ionis Expand Strategic Collaboration to Develop Drug Candidates for a Broad Range of Neurological Diseases
Transaction builds upon the productive collaboration that produced SPINRAZA ®  as well as two antisense drug candidates currently in the clinic, with the potential to advance up to seven more drug candidates to the clinic within the next two years The antisense platform developed by Ionis is an
Toggle Summary Presentations at the 2018 American Academy of Neurology Highlight the Broad Potential of Antisense Drugs for Neurological Diseases
-- Special conference session focused on therapeutic potential of antisense drugs to treat neurological diseases -- -- Fourteen presentations on Ionis' antisense drugs to treat neurological diseases, including SMA, amyloidosis, Huntington's disease, Alzheimer's disease, and ALS -- CARLSBAD, Calif.
Toggle Summary Akcea and Ionis Complete Licensing Transaction to Commercialize Inotersen for hATTR
  Akcea shareholders approved the transaction on April 16 at a Special Meeting of Stockholders                              Ionis licenses Akcea worldwide rights to inotersen and AKCEA-TTR-L Rx                CAMBRIDGE, Mass. and CARLSBAD, Calif., April 17, 2018 (GLOBE NEWSWIRE) --  Akcea
Toggle Summary Sarah Boyce Joins Akcea Therapeutics as President and Member of the Board of Directors
CAMBRIDGE, Mass. , April 17, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , today announced that, following today’s close of the transaction licensing Akcea the exclusive, worldwide rights to inotersen and AKCEA-TTR-L Rx , Sarah Boyce
Toggle Summary Ionis and AstraZeneca Advance New Drug for NASH
Ionis earns $30 million license fee for IONIS-AZ6-2.5-L Rx Third drug to enter development under strategic cardiovascular-renal-metabolic collaboration with AstraZeneca CARLSBAD, Calif. , April 9, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics,
Toggle Summary Ionis and Akcea Present New Data from ATTR Amyloidosis Program at 16th International Symposium on Amyloidosis
Continued benefit with long-term inotersen treatment observed in both quality of life (Norfolk-QOL-DN) and neuropathy (mNIS+7) measures in hATTR amyloidosis patients; Cardiac benefit with inotersen treatment observed in a Phase 2 study in patients with wild-type and hereditary ATTR cardiomyopathy
Toggle Summary Ionis Pharmaceuticals Provides Corporate Update at 2018 Annual Meeting of Stockholders
CARLSBAD, Calif. , March 23, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will present a general corporate update in conjunction with its 2018 Annual Meeting of Stockholders and Open House on Wednesday, May 23 at 2:10 p.m. Pacific Time ( 5:10 p.m.
Toggle Summary Ionis and Akcea Partner to Commercialize Inotersen for hATTR
Ionis licenses to Akcea worldwide rights to inotersen and IONIS-TTR-L Rx Collaboration advances commercial readiness for planned mid-2018 inotersen launch, positioning Akcea to successfully launch two drugs for significant rare diseases this year Ionis Chief Business Officer Sarah Boyce will join
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , March 6, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Cowen Annual Health Care Conference on Tuesday, March 13, 2018
Toggle Summary IONIS-HTT Rx (RG6042) Top-Line Data Demonstrate Significant Reductions of Disease-Causing Mutant Huntingtin Protein in People with Huntington's Disease
Phase 1/2 study first to demonstrate disease-modifying potential Up to ~60% reduction (mean ~40%) in the mutant huntingtin protein (mHTT) observed in the cerebral spinal fluid (CSF) of patients treated for three months with IONIS-HTT Rx (RG6042) at the two highest doses tested with mHTT levels
Toggle Summary Ionis Reports Fourth Quarter and Full Year 2017 Financial Results
SPINRAZA launch one of the most successful in rare disease history FY 2017 GAAP operating income of $25M; FY 2017 pro forma operating income of $111M 2017 year-end cash over $1B Mid-2018 launches planned for inotersen and volanesorsen Conference call and webcast today, February 27, 2018, at 11:30
Toggle Summary Ionis Licenses New Antisense Drug for Kidney Disease to AstraZeneca
Ionis earns $30 million license fee CARLSBAD, Calif. , Feb. 20, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed IONIS-AZ5-2.5 Rx (AZD2373) to the global, science-led biopharmaceutical company AstraZeneca (NYSE: AZN).
Toggle Summary The New England Journal of Medicine Publishes SPINRAZA® (nusinersen) Phase 3 Study Results in Individuals with Later-Onset Spinal Muscular Atrophy
SPINRAZA demonstrated stabilization or improvement in motor function in individuals with spinal muscular atrophy (SMA) where the natural history of the disease is a decline in motor function over time The majority of individuals treated with SPINRAZA demonstrated benefits in upper limb and general
Toggle Summary Ionis Pharmaceuticals to Hold 2017 Financial Results Conference Call
Webcast scheduled for Tuesday, February 27 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Feb. 13, 2018 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, February 27 at 11:30 a.m. Eastern Time to discuss its 2017 financial results
Toggle Summary Akcea Completes Enrollment in Phase 2b Study of AKCEA-APO(a)-LRx
CAMBRIDGE, Mass. , Feb. 07, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), today announced it had completed enrollment of a Phase 2b clinical study of investigational drug AKCEA-APO(a)-L Rx . Akcea is conducting the study in patients with high Lp(a) and established cardiovascular
Toggle Summary Ionis' Inotersen NDA Accepted for Priority Review by the FDA
PDUFA date of July 6, 2018 CARLSBAD, Calif. , Jan. 8, 2018 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its New Drug Application (NDA) for inotersen has been accepted for Priority Review by the U.S. Food and Drug Administration ( FDA ).
Toggle Summary Akcea Initiates Phase 2b Study of AKCEA-APOCIII-LRx in Patients with Hypertriglyceridemia and Established Cardiovascular Disease
CAMBRIDGE, Mass. , Jan. 05, 2018 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. , focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced the
Toggle Summary Ionis Pharmaceuticals Announces the Initiation of a Clinical Study of its First Orally Delivered Antisense Drug for the Treatment of Gastrointestinal Disorders
- Ionis Earns $5 Million Milestone Payment from Janssen CARLSBAD, Calif. , Dec. 21, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has earned a $5 million milestone payment associated with initiation and enrollment in a newly initiated Phase 1 clinical study
Toggle Summary Biogen and Ionis Enter into New Collaboration to Identify Novel Therapies for the Treatment of Spinal Muscular Atrophy
CAMBRIDGE, Mass. & CARLSBAD, Calif. --(BUSINESS WIRE)--Dec. 19, 2017-- Biogen (Nasdaq: BIIB) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that they have entered into a new collaboration agreement to identify new antisense oligonucleotide drug candidates for the treatment of spinal
Toggle Summary Ionis' License Agreement for Huntington's Disease Drug, IONIS-HTT Rx, Receives HSR Clearance
Ionis Earns $45 Million License Fee CARLSBAD, Calif. , Dec. 18, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that its license agreement with Roche to develop and commercialize IONIS-HTT Rx for the treatment of people with Huntington's disease (HD) has received
Toggle Summary Ionis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
CARLSBAD, Calif. , Dec. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the 36 th Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2018 at 7:30 a.m.
Toggle Summary Akcea Initiates Phase 2 Study of AKCEA-ANGPTL3-LRx in Patients with Hypertriglyceridemia, Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease (NAFLD)
Toggle Summary Ionis Pharmaceuticals Licenses IONIS-HTT Rx to Partner Following Successful Phase 1/2a Study in Patients with Huntington's Disease
Dose-dependent Reductions of Mutant Huntingtin Protein Observed Ionis Earns $45 Million License Fee CARLSBAD, Calif. , Dec. 11, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Roche has exercised its option to license IONIS-HTT Rx following the completion of a
Toggle Summary Ionis Pharmaceuticals to Present at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference
CARLSBAD, Calif. , Dec. 7, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference on Thursday, December 14,
Toggle Summary Ionis Pharmaceuticals Licenses Second Orally Delivered Antisense Drug to Janssen
- IONIS-JBI2-2.5 Rx designed to treat GI autoimmune disease - Ionis Earns $5 Million License Fee from Janssen CARLSBAD, Calif. , Nov. 16, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has licensed a second orally delivered Generation 2.5 antisense drug to
Toggle Summary Akcea and Ionis Announce Acceptance of Marketing Applications in U.S., EU and Canada for Volanesorsen for the Treatment of FCS
FDA Prescription Drug User Fee Act goal date set for August 30, 2018 CAMBRIDGE, Mass., Nov. 15, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious
Toggle Summary Akcea Initiates AKCEA-ANGPTL3-LRx Phase 2 Program in Patients with Rare Hyperlipidemias
CAMBRIDGE, Mass., Nov. 13, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS), focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today announced
Toggle Summary Ionis Licenses Novel Antisense Drug for the Treatment of Centronuclear Myopathy to Dynacure
Ionis earns $5 million license fee from Dynacure CARLSBAD, Calif. and STRASBOURG, France , Nov. 9, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) and Dynacure announced today that Dynacure has licensed IONIS-DNM2-2.5 Rx (Dyn101), a Generation 2.5 antisense drug targeting dynamin 2
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Nov. 8, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Stifel 2017 Healthcare Conference on Wednesday, November 15, 2017
Toggle Summary Ionis Announces Management Transitions
Brett Monia to become Chief Operating Officer Lynne Parshall to become Senior Strategic Advisor to Ionis CARLSBAD, Calif. , Nov. 7, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today management transitions to be effective January 15, 2018 . Brett P.
Toggle Summary Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2017
- CONTINUED IMPROVEMENT IN OPERATING RESULTS WITH YEAR TO DATE 2017 OPERATING INCOME OF $26 MILLION AND PRO FORMA OPERATING INCOME OF $90 MILLION - STRENGTHENED FINANCIAL POSITION WITH CASH OF OVER $1 BILLION Conference Call and Webcast Tuesday, November 7, 11:30 a.m.
Toggle Summary Ionis Announces Submission of New Drug Application (NDA) for Inotersen to the U.S. FDA
CARLSBAD, Calif. , Nov. 6, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the company submitted a new drug application (NDA) to the U.S. Food and Drug Administration for inotersen, an investigational medicine for the treatment of patients with hereditary TTR
Toggle Summary Ionis Announces Submission of Marketing Authorization Application for Inotersen to the European Medicines Agency
Inotersen MAA to be reviewed under EMA Accelerated Assessment program CARLSBAD, Calif. , Nov. 3, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that the company submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for
Toggle Summary Ionis Presents New Data from NEURO-TTR Study at European ATTR Amyloidosis Meeting
Significant benefit in quality of life and disease severity endpoints observed in inotersen-treated patients compared to placebo-treated patients Consistent and significant differences observed between inotersen-treated and placebo-treated patients independent of disease stage, types of mutation,
Toggle Summary The New England Journal of Medicine Publishes First Phase 3 Study Results of SPINRAZA® for the Treatment of Spinal Muscular Atrophy
SPINRAZA, the first and only approved treatment for spinal muscular atrophy (SMA), is supported by the largest well-controlled SMA clinical development program conducted to date The majority of infants treated with SPINRAZA in the ENDEAR study achieved motor milestones compared to untreated infants
Toggle Summary Ionis to Present Inotersen NEURO-TTR Phase 3 Study Results at 1st European ATTR Amyloidosis Meeting
Company to host webcast conference call on Thursday, November 2 at 7:00 a.m. Eastern Time CARLSBAD, Calif. , Nov. 1, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Thursday, November 2 at 7:00 a.m.
Toggle Summary Akcea and Ionis Report Positive Phase 1/2a Data with AKCEA-APOCIII-LRx
Akcea expects to initiate Phase 2b in patients with hypertriglyceridemia with established cardiovascular disease by the end of this year CAMBRIDGE, Mass., Oct. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
Toggle Summary Ionis and Biogen Win Prestigious Prix Galien Best Biotechnology Product Award for SPINRAZA
CARLSBAD, Calif. , Oct. 27, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that Ionis and Biogen have been awarded the Prix Galien USA Award for the Best Biotechnology Product in 2017 for SPINRAZA ® (nusinersen). The Prix Galien USA Award recognizes extraordinary
Toggle Summary Ionis Pharmaceuticals Announces Plans to Open Expanded Access Program to Provide Inotersen to Patients with Hereditary TTR Amyloidosis in the U.S.
- Ionis plans to open multiple sites in the U.S. CARLSBAD, Calif. , Oct. 27, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it plans to open an expanded access program (EAP) for eligible patients with hereditary transthyretin amyloidosis (hATTR) with
Toggle Summary Ionis Pharmaceuticals to Hold Third Quarter 2017 Financial Results Webcast
Webcast scheduled for Tuesday, November 7 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , Oct. 24, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, November 7 at 11:30 a.m. Eastern Time to discuss its third quarter 2017
Toggle Summary Ionis Enters into Collaboration with Seventh Sense Biosystems to Support Development of Improved Blood Collection and Diagnostic Device
CARLSBAD, Calif. , Oct. 18, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has entered a collaboration with Seventh Sense Biosystems, Inc. (7SBio), a private medical device company developing TAP™, a novel, push-button, blood collection device to make blood
Toggle Summary Ionis Presents New Data from NEURO-TTR Study and Highlights Programs from Its Neurological Disease Franchise at ANA Congress
Inotersen treatment resulted in a 20-point benefit in mNIS+7 compared to placebo Ionis antisense programs featured in 11 platform and poster presentations at ANA CARLSBAD, Calif. , Oct. 15, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today
Toggle Summary Ionis Pharmaceuticals Initiates Clinical Study of IONIS-MAPT Rx in Patients with Alzheimer's Disease
Antisense drug designed to reduce tau protein in the CNS Ionis earns $10 million milestone payment from Biogen CARLSBAD, Calif. , Oct. 13, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has initiated a Phase 1/2a clinical study of IONIS-MAPT Rx in patients
Toggle Summary Biogen’s SPINRAZA® (nusinersen) Data Show Earlier Treatment Initiation May Lead to Improved Motor Function Across a Broad Population of People Living with Spinal Muscular Atrophy
New data from Phase 3 ENDEAR study demonstrated earlier initiation of treatment with SPINRAZA may improve motor function outcomes in infants with Spinal Muscular Atrophy (SMA) Phase 2 EMBRACE interim analysis showed greater motor milestone achievement in infants and children treated with SPINRAZA,
Toggle Summary Akcea and Ionis Announce Filing of New Drug Submission for Volanesorsen to Health Canada
Health Canada grants priority review for volanesorsen NDS filing Volanesorsen could be the first approved treatment for patients with FCS CAMBRIDGE, Mass. and CARLSBAD, Calif., Sept. 12, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc.
Toggle Summary New Data Presented at European Society for Medical Oncology Meeting Demonstrate Antitumor Activity with IONIS-STAT3-2.5 Rx in Combination with Imfinzi
29% Objective Response Rate and 57% Disease Control Rate in Combination with Immune Checkpoint Inhibitor Treatment in Patients with Head and Neck Cancer Four Complete Responses and Four Partial Responses Observed in 28-patient Study CARLSBAD, Calif. , Sept.
Toggle Summary Akcea and Ionis Announce Submission of New Drug Application for Volanesorsen to the U.S. FDA
<p>CAMBRIDGE, Mass., Aug. 31, 2017 (GLOBE NEWSWIRE) -- Akcea Therapeutics, Inc. (NASDAQ:AKCA), an affiliate of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders, today
Toggle Summary Ionis Earns $40 Million SPINRAZA Regulatory Milestone Payment from Biogen
CARLSBAD, Calif. , Aug. 30, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $40 million milestone payment from Biogen associated with the pricing approval of SPINRAZA ® (nusinersen) in Japan . SPINRAZA was approved for individuals with
Toggle Summary Ionis Recommends Shareholders Reject The Below-The-Market Mini-Tender Offer By TRC Capital Corporation
CARLSBAD, Calif. , Aug. 24, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today announced that it has received notice of an unsolicited mini-tender offer by TRC Capital Corporation of Ontario, Canada to purchase up to 2.5 million shares of Ionis' common stock at a price of $44.88
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
CARLSBAD, Calif. , Aug. 17, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS), the leader in antisense therapeutics, today announced that management will present a company overview at the following investor conferences: Southern California Investor Conference on Thursday, August 24,
Toggle Summary Ionis to Independently Advance Inotersen and IONIS-FB-L Rx
Inotersen on Track for Marketing Authorization Filings This Year Conference Call Webcast Friday, August 11, 8:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif. , Aug. 11, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported that the Company has retained all rights to
Toggle Summary Ionis Provides Improved 2017 Guidance Following Strong Financial Performance
Conference Call Webcast Tuesday, August 8, 11:30 a.m. ET at www.ionispharma.com CARLSBAD, Calif., Aug. 8, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) today reported improved financial results with an operating loss of $1.7 million and operating income of $12.3 million for
Toggle Summary Akcea Reports Financial Results and Highlights for Second Quarter 2017
Toggle Summary Akcea and Ionis Announce Submission of Marketing Authorization Application for Volanesorsen to the European Medicines Agency
CAMBRIDGE, Mass. and CARLSBAD, Calif. , July 27, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. (NASDAQ: AKCA) and Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that a marketing authorization application (MAA) has been submitted to the European Medicines Agency (EMA) for volanesorsen
Toggle Summary Ionis Pharmaceuticals to Hold Second Quarter 2017 Financial Results Webcast
Webcast scheduled for Tuesday, August 8 at 11:30 a.m. Eastern Time CARLSBAD, Calif. , July 25, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it will host a live webcast on Tuesday, August 8 at 11:30 a.m. Eastern Time to discuss its second quarter 2017
Toggle Summary Akcea Therapeutics Announces Closing of Initial Public Offering
CAMBRIDGE, Mass. , July 19, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the closing of its initial public offering of 17,968,750 shares common stock at a public offering price of $8.00 per share, including 2,343,750 shares of common stock issued upon full exercise by the
Toggle Summary Ionis Earns $10 Million Milestone Payment from Biogen for Advancing a New Program in its Neurology Collaboration
CARLSBAD, Calif. , July 17, 2017 /PRNewswire/ --  Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) announced today that it has earned a $10 million milestone payment from Biogen associated with the validation of an undisclosed neurological disease target. Ionis and Biogen have a broad strategic
Toggle Summary Akcea Therapeutics Announces Pricing of Initial Public Offering
CAMBRIDGE, Mass. , July 13, 2017 /PRNewswire/ -- Akcea Therapeutics, Inc. today announced the pricing of its initial public offering of 15,625,000 shares common stock at a public offering price of $8.00 per share, for gross proceeds of $125.0 million before underwriting discounts and commissions
Toggle Summary New Data Presented at Peripheral Nerve Society Meeting Further Support Potential Benefit of Inotersen
Significant benefit observed for both clinical measurements of neurological disease progression and quality of life at 8 and 15 months in patients with FAP CARLSBAD, Calif. , July 10, 2017 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (NASDAQ: IONS) presented new top-line data from the Phase 3
Toggle Summary New Data Reaffirm Clinically Meaningful Benefit of SPINRAZA®(nusinersen) in Individuals with Spinal Muscular Atrophy Across Disease Severity
Toggle Summary Enrollment in Phase 1/2a Study of IONIS-HTT Rx in Patients with Huntington's Disease Completed and Open-Label Extension Study to Open in 2H 2017
Toggle Summary Akcea Therapeutics Launches Proposed Initial Public Offering
Toggle Summary SPINRAZA® (nusinersen) Approved in the European Union
Toggle Summary Akcea Announces Publication in The New England Journal of Medicine of Data with AKCEA-ANGPTL3-L Rx Showing Favorable Cardiometabolic Effects
Toggle Summary Ionis Pharmaceuticals Announces Phase 3 NEURO-TTR Study of Inotersen (IONIS-TTR Rx) Meets Both Primary Endpoints
Toggle Summary Ionis Pharmaceuticals Provides Corporate Update at 2017 Annual Meeting of Stockholders
Toggle Summary Ionis Pharmaceuticals to Present at Bank of America Merrill Lynch 2017 Healthcare Conference
Toggle Summary Akcea Therapeutics Announces Appointment of Edward Fitzgerald to Board of Directors
Toggle Summary Ionis Reports Financial Results and Highlights for First Quarter 2017
Toggle Summary Ionis Pharmaceuticals to Hold First Quarter 2017 Financial Results Webcast
Toggle Summary Final Phase 3 Study Data Show SPINRAZA® (nusinersen) Significantly Improved Motor Function in Children with Later-Onset Spinal Muscular Atrophy
Toggle Summary Biogen’s SPINRAZA® (nusinersen) Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
Toggle Summary Ionis Enters into Collaboration with Ribo to Advance RNA-Targeted Therapeutics in China
Toggle Summary Akcea Initiates Phase 2 Study of AKCEA-APO(a)-L Rx in Patients with High Lp(a) and Cardiovascular Disease
Toggle Summary Ionis Pharmaceuticals to Present at Needham Healthcare Conference
Toggle Summary Akcea Therapeutics Announces Three Additions to Board of Directors
Toggle Summary Akcea Therapeutics Files Registration Statement for Proposed Initial Public Offering
Toggle Summary Akcea and Ionis Announce Positive Results from Pivotal Study of Volanesorsen in Patients with Familial Chylomicronemia Syndrome (FCS)
Toggle Summary Ionis' 2016 Financial Results Outperform Financial Guidance
Toggle Summary Ionis and Akcea Close on Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Toggle Summary Ionis Pharmaceuticals to Hold 2016 Financial Results Conference Call
Toggle Summary Ionis Earns $75 Million from Bayer for Advancing IONIS-FXI Rx and IONIS-FXI-L Rx
Toggle Summary Ionis Earns $5 Million Milestone Payment from Biogen for Advancing a New Program Under Its Broad Neurology Strategic Collaboration
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences
Toggle Summary New Data Show SPINRAZA™ (nusinersen) Significantly Reduces Risk of Death or Permanent Ventilation in Infantile-Onset Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals Significantly Improves Upon 2016 Financial Guidance
Toggle Summary Ionis and Akcea Enter into Strategic Collaboration with Global Pharmaceutical Company to Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
Toggle Summary Ionis Pharmaceuticals Reports Positive Data from Phase 2 Study of IONIS-GCGR Rx in Patients with Type 2 Diabetes
Toggle Summary SPINRAZA™ (nusinersen) Approved in U.S. to Treat Broad Range of Patients with Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals Earns Milestone Payment from Janssen for Advancing a New Program Under GI Collaboration
Toggle Summary Ionis and AstraZeneca Advance First Generation 2.5 LICA Drug into Preclinical Development to Treat Cardiovascular Disease
Toggle Summary Akcea and Ionis Announce Positive Results from COMPASS Phase 3 Study of Volanesorsen
Toggle Summary Ionis Earns $28 Million from AstraZeneca for a New Drug to Treat Cancer
Toggle Summary Ionis Pharmaceuticals to Host a Pipeline Update Webcast
Toggle Summary Ionis Pharmaceuticals to Present at the 35th Annual J.P. Morgan Healthcare Conference
Toggle Summary Ionis Pharmaceuticals to Present at the BMO Capital Markets Prescriptions for Success Healthcare Conference
Toggle Summary Ionis Pharmaceuticals Reports Positive Clinical Data from IONIS-ANGPTL3-L Rx
Toggle Summary Ionis Pharmaceuticals Reports Financial Results and Highlights for Third Quarter 2016
Toggle Summary Biogen and Ionis Pharmaceuticals Announce SPINRAZA (nusinersen) Meets Primary Endpoint at Interim Analysis of Phase 3 CHERISH Study in Later-Onset Spinal Muscular Atrophy
Toggle Summary Ionis Pharmaceuticals to Present at Upcoming Investor Conferences